

# John A Bittl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8738684/publications.pdf>

Version: 2024-02-01

136  
papers

16,346  
citations

57758

44  
h-index

17592

121  
g-index

141  
all docs

141  
docs citations

141  
times ranked

11381  
citing authors

#	ARTICLE	IF	CITATIONS
1	Putting the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Practice. JACC: Case Reports, 2022, 4, 31-35.	0.6	2
2	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	2.8	561
3	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 197-215.	2.8	150
4	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001039.	1.6	159
5	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
6	Does Bypass Surgery or Percutaneous Coronary Intervention Improve Survival in Stable Ischemic Heart Disease?. JACC: Cardiovascular Interventions, 2022, , .	2.9	1
7	Multivessel Percutaneous Coronary Intervention During ST-Elevation Myocardial Infarction—A Dickensian Debate That Never Ends. JAMA Cardiology, 2021, 6, 580.	6.1	0
8	Dialysis access intervention: Techniques for the interventional cardiologist. Progress in Cardiovascular Diseases, 2021, 65, 84-88.	3.1	1
9	Does Platelet Reactivity Testing Predict Post-Operative Bleeding Risk?. Journal of the American College of Cardiology, 2021, 77, 1287-1289.	2.8	1
10	Antithrombotic Therapy after Acute Coronary Syndromes. New England Journal of Medicine, 2021, 384, 1872-1874.	27.0	1
11	Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2021, 79, 129-129.	2.8	3
12	When to Believe Unexpected Results for Ticagrelor or Prasugrel. JACC: Cardiovascular Interventions, 2020, 13, 2248-2250.	2.9	3
13	Integrating the ABC-Bleeding Risk Score Into Practice. JAMA Network Open, 2020, 3, e2016126.	5.9	1
14	Percutaneous Coronary Intervention for Chronic Total Occlusions. Circulation: Cardiovascular Interventions, 2020, 13, e008920.	3.9	0
15	The ABCD-GENE Score for Clopidogrel Response. JACC: Cardiovascular Interventions, 2020, 13, 618-620.	2.9	4
16	Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices. JACC: Cardiovascular Interventions, 2019, 12, 2528-2537.	2.9	5
17	Invasive Cardiac Procedures Increase Bleeding in Frail Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2018, 11, 2297-2299.	2.9	1
18	Using Ticagrelor to Prevent Recurrent Type 1 and Type 2 Myocardial Infarctions: Boon or Bane?. Journal of the American Heart Association, 2018, 7, e010996.	3.7	1

#	ARTICLE	IF	CITATIONS
19	An Update on Radial Artery Access and Best Practices for Transradial Coronary Angiography and Intervention in Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e000035.	3.9	347
20	A Swing and a Miss for the DAPT Score. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1079-1080.	2.8	2
21	DAPT rules. <i>EuroIntervention</i> , 2018, 13, 1864-1868.	3.2	0
22	What Do Noninferiority Trials Say About Coronary Stents?. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 265-267.	2.9	0
23	Treatment Strategies for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 206-207.	2.9	0
24	Bivalirudin or heparin for radial access?. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1166-1167.	1.7	0
25	Much Ado About Nothing?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	9
26	Using Absolute Event Rates to See What Works in Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1376-1378.	2.8	5
27	Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	64
28	The Prematurely Stopped Clinical Trial. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1199-1201.	2.9	3
29	Why Radial Access Is Better. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1435-1437.	2.9	1
30	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	2.8	1,232
31	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2016, 134, e156-78.	1.6	105
32	Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1116-1139.	2.8	154
33	Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2016, 1, 226.	6.1	6
34	PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1066-1081.	2.8	60
35	Extended Dual Antiplatelet Therapy in Patients With Prior Myocardial Infarction. <i>JAMA Cardiology</i> , 2016, 1, 629.	6.1	2
36	Bleeding Versus Ischemic Events. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2387-2389.	2.9	1

#	ARTICLE	IF	CITATIONS
37	How long should dual antiplatelet therapy be used in diabetic patients after implantation of drug-eluting stents?. <i>Current Opinion in Cardiology</i> , 2016, 31, 677-682.	1.8	3
38	Meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1203-1210.	1.7	9
39	The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents. <i>Current Cardiology Reports</i> , 2016, 18, 8.	2.9	4
40	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1235-1250.	2.8	684
41	Outcomes after multivessel or culprit vessel intervention for <scp>ST</scp>-elevation myocardial infarction in patients with multivessel coronary disease: A <scp>B</scp>-ayesian cross-design meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, S15-22.	1.7	13
42	Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002789.	3.9	13
43	Go Set a Watchman?. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1933-1934.	2.9	0
44	Percutaneous Coronary Intervention for Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 254-256.	2.9	0
45	Treatment of Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2015, 65, 544-545.	2.8	3
46	2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, e5-e23.	0.8	97
47	Percutaneous Coronary Interventions in the Diabetic Patient. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001944.	3.9	27
48	Everolimus-Eluting Coronary Stents for Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1221-1223.	2.8	0
49	Dual-Antiplatelet Therapy for Diabetic Patients After Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1102-1104.	2.8	4
50	Bayesian Inference Supports the Use of Bypass Surgery Over Percutaneous Coronary Intervention To Reduce Mortality in Diabetic Patients with Multivessel Coronary Disease. <i>International Journal of Statistics in Medical Research</i> , 2015, 4, 26-34.	1.0	3
51	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Circulation</i> , 2014, 130, 1749-1767.	1.6	685
52	Response to Letters Regarding Article, "Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease". <i>Circulation</i> , 2014, 129, e309.	1.6	0
53	Treatment of Atherosclerotic Renovascular Disease. <i>New England Journal of Medicine</i> , 2014, 370, 78-79.	27.0	9
54	A proposal to reduce contrast nephropathy: Eliminate the NPO order. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 913-914.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Family presence during catheterization procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 341-341.	1.7	3
56	2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1929-1949.	2.8	656
57	Deconstructing Stent Polymers. <i>Journal of the American College of Cardiology</i> , 2014, 63, 308-309.	2.8	4
58	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E266-355.	1.7	97
59	Abciximab During Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1455-1457.	2.8	4
60	Bayesian Methods Affirm the Use of Percutaneous Coronary Intervention to Improve Survival in Patients With Unprotected Left Main Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 2177-2185.	1.6	95
61	Chelation Therapy and Cardiovascular Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 430.	7.4	3
62	Beware of large treatment effects in small clinical trials: Lessons from trials of coronary atheroablative devices. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 292-293.	1.7	0
63	Interventions for Failing Hemodialysis Access. , 2013, , 421-429.		0
64	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	2.8	2,027
65	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 58, e123-e210.	2.8	665
66	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
67	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. <i>Circulation</i> , 2011, 124, 2610-2642.	1.6	451
68	Economic analysis of angiography and preemptive angioplasty to prevent hemodialysis access thrombosis. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 14-21.	1.7	21
69	Catheter Interventions for Hemodialysis Fistulas and Grafts. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1-11.	2.9	94
70	Bioresorbable Stents. <i>Circulation</i> , 2010, 122, 2236-2238.	1.6	8
71	Adaptive remodeling of hypoplastic hemodialysis fistulas salvaged with angioplasty. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 974-978.	1.7	8
72	Venous rupture during percutaneous treatment of hemodialysis fistulas and grafts. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 1097-1101.	1.7	34

#	ARTICLE	IF	CITATIONS
73	Physical aspects of excimer laser angioplasty for undilatable lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 808-809.	1.7	13
74	Damage Control for Renal Artery Stenting. <i>Circulation</i> , 2008, 117, 2724-2726.	1.6	4
75	Predictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial. <i>American Journal of Cardiology</i> , 2007, 100, 1364-1369.	1.6	315
76	The Future of an Illusion—Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2380-2383.	2.8	3
77	Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. <i>American Heart Journal</i> , 2006, 152, 157-163.	2.7	13
78	Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. <i>American Heart Journal</i> , 2006, 152, 149-154.	2.7	28
79	The truth about activated clotting time measurements. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 338-339.	1.7	3
80	Prospective assessment of hemodialysis access patency after percutaneous intervention: Cox proportional hazards analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 309-315.	1.7	16
81	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005, 26, 2396-2403.	2.2	24
82	Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization—REPLACE-2 Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 696.	7.4	363
83	Concomitant Peripheral Arterial Disease and Coronary Artery Disease. <i>Circulation</i> , 2004, 109, 3136-3144.	1.6	30
84	Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td). <i>Journal of Cardiology</i> , 2004, 93, 1092-1096.	1.6	215
85	Meta-Analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. <i>Journal of the American College of Cardiology</i> , 2004, 43, 936-942.	2.8	109
86	Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. <i>American Journal of Cardiology</i> , 2003, 92, 919-923.	1.6	92
87	Cutting balloon angioplasty for undilatable venous stenoses causing dialysis graft failure. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 524-526.	1.7	42
88	Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. <i>Journal of the American College of Cardiology</i> , 2003, 41, 386-393.	2.8	99
89	Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 853.	7.4	1,074
90	Coronary Flow Velocity and Disturbed Flow Predict Adverse Clinical Outcome After Coronary Angioplasty. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1334-1340.	2.4	16

#	ARTICLE	IF	CITATIONS
91	Percutaneous therapy of dialysis access failure. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 56, 157-161.	1.7	8
92	Argatroban for percutaneous coronary interventions: Hit or miss?. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 57, 185-186.	1.7	0
93	Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. <i>American Heart Journal</i> , 2001, 142, 952-959.	2.7	324
94	From confusion to clarity: Direct thrombin inhibitors for patients with heparin-induced thrombocytopenia. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 52, 473-475.	1.7	2
95	Cardiovascular disease in dialysis patients: Double trouble. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 54, 464-465.	1.7	0
96	Cholesterol embolization syndrome: Unifying principles. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 51, 326-327.	1.7	9
97	Clinical Outcomes of Bivalirudin for Ischemic Heart Disease. <i>Circulation</i> , 1999, 100, 2049-2053.	1.6	101
98	No-touch technique for reducing aortic wall trauma during renal artery stenting. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 46, 245-248.	1.7	76
99	Creatine kinase leaks, myocardial necrosis, and prognosis after percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 46, 303-304.	1.7	1
100	Optimizing the benefits of renal artery stenting. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 47, 173-174.	1.7	1
101	A safety net for saphenous vein graft perforations. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 387-387.	1.7	0
102	Effect of transient abrupt vessel closure during otherwise successful angioplasty for unstable angina on clinical outcome at six months. <i>Journal of the American College of Cardiology</i> , 1999, 33, 73-78.	2.8	19
103	Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. <i>American Journal of Cardiology</i> , 1998, 82, 511-515.	1.6	30
104	Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. <i>American Journal of Cardiology</i> , 1998, 82, 50P-56P.	1.6	34
105	A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. <i>American Journal of Cardiology</i> , 1998, 82, 43P-49P.	1.6	41
106	Laser wire for crossing chronic total occlusions: "Learning phase" results from the U.S. TOTAL trial. , 1998, 44, 235-243.		13
107	Myonecrosis After Revascularization Procedures. <i>Journal of the American College of Cardiology</i> , 1998, 31, 241-251.	2.8	459
108	Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. <i>Chest</i> , 1998, 114, 728S-741S.	0.8	44



#	ARTICLE	IF	CITATIONS
109	Laser wire for crossing chronic total occlusions: "Learning phase" results from the U.S. TOTAL trial. <i>Catheterization and Cardiovascular Diagnosis</i> , 1998, 44, 235-243.	0.3	2
110	Bivalirudin Compared With Heparin During Coronary Angioplasty for Thrombus-Containing Lesions. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1264-1269.	2.8	19
111	Excimer Laser Coronary Angioplasty: The New Approaches to Coronary Intervention (NACI) Experience. <i>American Journal of Cardiology</i> , 1997, 80, 99K-105K.	1.6	27
112	Coronary stent occlusion: Thrombus horribilis. <i>Journal of the American College of Cardiology</i> , 1996, 28, 368-370.	2.8	26
113	Excimer laser angioplasty: Focus on total occlusions. <i>American Journal of Cardiology</i> , 1996, 78, 823-824.	1.6	6
114	Excimer laser-facilitated angioplasty for undilatable coronary narrowings. <i>American Journal of Cardiology</i> , 1996, 78, 1045-1047.	1.6	45
115	Advances in Coronary Angioplasty. <i>New England Journal of Medicine</i> , 1996, 335, 1290-1302.	27.0	230
116	Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology. <i>Circulation</i> , 1996, 93, 431-439.	1.6	66
117	Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. <i>Chest</i> , 1995, 108, 486S-501S.	0.8	56
118	Orthodeoxia-platypnea due to intracardiac shunting relief with transcatheter double umbrella closure. <i>Catheterization and Cardiovascular Diagnosis</i> , 1995, 36, 247-250.	0.3	64
119	The Changing Profile of Patient Selection, Procedural Techniques, and Outcomes in Excimer Laser Coronary Angioplasty. <i>Journal of Interventional Cardiology</i> , 1995, 8, 653-660.	1.2	10
120	Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina. <i>New England Journal of Medicine</i> , 1995, 333, 764-769.	27.0	497
121	Effect of intracoronary saline infusion on dissection during excimer laser coronary angioplasty: A randomized trial. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1264-1269.	2.8	89
122	Length of Hospital Stay and Complications After Percutaneous Transluminal Coronary Angioplasty. <i>Circulation</i> , 1995, 92, 311-319.	1.6	46
123	Early and Late Quantitative Angiographic Results of Vein Graft Lesions Treated by Excimer Laser With Adjunctive Balloon Angioplasty. <i>Circulation</i> , 1995, 92, 348-356.	1.6	28
124	Excimer Laser Coronary Angioplasty. <i>Cardiology Clinics</i> , 1994, 12, 585-593.	2.2	0
125	Mitral Valve Balloon Dilatation: Long-Term Results. <i>Journal of Cardiac Surgery</i> , 1994, 9, 213-217.	0.7	1
126	Acute complications of excimer laser coronary angioplasty: A detailed analysis of multicenter results. <i>Journal of the American College of Cardiology</i> , 1994, 23, 1305-1313.	2.8	85



#	ARTICLE	IF	CITATIONS
127	Analysis of late lumen narrowing after excimer laser-facilitated coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1994, 23, 1314-1320.	2.8	31
128	Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. <i>American Journal of Cardiology</i> , 1993, 72, 544-550.	1.6	62
129	Coronary artery perforation during excimer laser coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1993, 21, 1158-1165.	2.8	139
130	Directional Coronary Atherectomy versus Balloon Angioplasty. <i>New England Journal of Medicine</i> , 1993, 329, 273-274.	27.0	26
131	Transcatheter umbrella closure of valvular and paravalvular leaks. <i>Journal of the American College of Cardiology</i> , 1992, 20, 1371-1377.	2.8	201
132	Wire-Guided Excimer Laser Coronary Angioplasty: Instrument Selection, Lesion Characterization, and Operator Technique. <i>Journal of Interventional Cardiology</i> , 1992, 5, 275-291.	1.2	2
133	Clinical success, complications and restenosis rates with excimer laser coronary angioplasty. <i>American Journal of Cardiology</i> , 1992, 70, 1533-1539.	1.6	137
134	Successful treatment of an excimer laser-associated coronary artery perforation with the stack perfusion catheter. <i>Catheterization and Cardiovascular Diagnosis</i> , 1991, 22, 118-123.	0.3	22
135	Peak left ventricular pressure during percutaneous aortic balloon valvuloplasty: Clinical and echocardiographic correlations. <i>Journal of the American College of Cardiology</i> , 1989, 14, 135-142.	2.8	5
136	Biochemical responses of myocardial cells in culture to oxygen and glucose deprivation. <i>Biochemical and Biophysical Research Communications</i> , 1974, 59, 749-756.	2.1	31